Back
ESC Professional Premium Access

Direct cost analysis of genetic testing for CYP2C19*2 and *3 loss of function variants in percutaneous coronary intervention patients

Session: Coronary artery disease - Pharmacotherapy 1
Topic: Pharmacotherapy
Speaker: Doctor S. Huxley (Rochester, US)
Event: ESC Congress 2022

Congress Presentation

Add to my library

Like

About the speaker

Doctor Samuel Huxley

Mayo Clinic Hospital-Rochester, Rochester (United States of America)
0 follower

4 more presentations in this session

Sodium-glucose co-transporter-2 inhibitors after acute myocardial infarction in type 2 diabetes patients: a population-based investigation from South Korea

Speaker: Doctor O. Kwon (Seoul, KR)

Access
Abstract
Slides
Like
Thumbnail

Activation of mitochondrial telomerase reverses relative lymphopenia post myocardial infarction: results from the randomised, double-blinded TACTIC phase IIa pilot trial

Speaker: Professor I. Spyridopoulos (Newcastle-Upon-Tyne, GB)

Access
Abstract
Slides
Like
Thumbnail

Blood pressure and clinical outcomes in patients with diabetes and stable coronary artery disease in THEMIS

Speaker: Doctor M. Pareek (Copenhagen, DK)

Access
Abstract
Slides
Like
Thumbnail

Effect of rivaroxaban monotherapy vs. combination with anti-platelet therapy in patients with atrial fibrillation and stable coronary artery disease across different body mass index categories

Speaker: Doctor M. Ishii (Kumamoto, JP)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Coronary artery disease - Pharmacotherapy 1

Speakers: Doctor S. Huxley, Doctor O. Kwon, Professor I. Spyridopoulos, Doctor M. Pareek, Doctor M. Ishii
Access
Like
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources